IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10829448 B1

PDFFull Text
Date of Patent:
Nov. 10, 2020

Filed:

Apr. 03, 2019

Substituted benzoimidazoles as modulators of ror-γ

Applicant:

Vitae Pharmaceuticals, Llc, Madison, NJ (US);

Inventors:

David A. Claremon, Maple Glen, PA (US);

Lawrence Wayne Dillard, Yardley, PA (US);

Yi Fan, Doylestown, PA (US);

Stephen D. Lotesta, Burlington, NJ (US);

Suresh B. Singh, Kendall Park, NJ (US);

Colin M. Tice, Maple Glen, PA (US);

Wei Zhao, North Potomac, MD (US);

Linghang Zhuang, Chalfont, PA (US);

Assignee:

Vitae Pharmaceuticals, LLC, Madison, NJ (US);

Attorneys:

McCarter & English, LLP

Michael J. DeGrazia

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/4184 (2006.01); C07D 235/04 (2006.01); C07D 209/10 (2006.01); C07D 405/14 (2006.01); C07D 401/06 (2006.01); C07D 235/10 (2006.01); C07D 235/12 (2006.01); C07D 401/12 (2006.01); C07D 405/06 (2006.01); C07D 471/04 (2006.01); C07D 235/26 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
C07D 209/10 (2013.01); C07D 235/10 (2013.01); C07D 235/12 (2013.01); C07D 235/26 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/06 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07B 2200/07 (2013.01); C07B 2200/09 (2013.01);
Abstract

Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Such derivatives include e.g., those having the Formula II: as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Find Patent Forward Citations

Loading…